KCNH1
ENSG00000143473
Target class
Ion channel
Chromosome
1
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- KCNH1
- Gene name
- Potassium voltage-gated channel subfamily H member 1
- Gene symbol
- KCNH1
- Protein name
- Voltage-gated delayed rectifier potassium channel KCNH1 (Ether-a-go-go potassium channel 1) (EAG channel 1) (h-eag) (hEAG1) (Potassium voltage-gated channel subfamily H member 1) (Voltage-gated potassium channel subunit Kv10.1)
- Kv10.1
- eag
- h-eag
- eag1
- hEAG
- K(V)10.1
- Gene biotype
- Protein coding
- Gene family
- Potassium voltage-gated channels|PAS domain containing
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 5
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 6.42
- Tissue specificity (Gini)
- 0.718
- Tissue specificity (tau)
- 0.93
- KEGG gene identifiers
- hsa:3756
- Reactome pathways
- R-HSA-1296072
- Protein interaction confidence
- 0.773
- Protein interaction partners
- 10
- End position
- 211134183
- Start position
- 210676823
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Nucleus inner membrane
- Multi-pass membrane protein . Cell projection, dendrite . Cell projection, axon . Presynaptic cell membrane . Perikaryon . Postsynaptic density membrane . Early endosome membrane . Note=Perinuclear KCNH1 is located to NPC-free islands.
- Vesicles
- PubMed 10880439
- PubMed 11943152
- PubMed 21559285
- PubMed 22732247
- PubMed 22841712
- PubMed 25556795
- PubMed 27005320
- PubMed 27325704
- PubMed 27618660
- PubMed 9738473
- Tissue specificity (tau)
- 0.929701
- Expression inequality (Gini)
- 0.717657
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 6.42
- Brain - Cerebellum
- 6
- Brain - Frontal Cortex (BA9)
- 3.03
- Brain - Cortex
- 2.41
- Testis
- 1.13
Expression in transcripts per million
- Brain - Cerebellar Hemisphere6.42
- Brain - Cerebellum6
- Brain - Frontal Cortex (BA9)3.03
- Brain - Cortex2.41
- Testis1.13
- Brain - Anterior cingulate cortex (BA24)0.89
- Cervix - Ectocervix0.86
- Brain - Nucleus accumbens (basal ganglia)0.77
- Brain - Spinal cord (cervical c-1)0.67
- Cervix - Endocervix0.58
- Brain - Caudate (basal ganglia)0.58
- Nerve - Tibial0.47
- Small Intestine - Terminal Ileum0.4
- Brain - Hypothalamus0.39
- Brain - Hippocampus0.38
- Pituitary0.36
- Brain - Putamen (basal ganglia)0.36
- Brain - Amygdala0.34
- Fallopian Tube0.32
- Vagina0.28
- Colon - Sigmoid0.26
- Prostate0.24
- Bladder0.24
- Colon - Transverse0.23
- Uterus0.21
And 29 more, listed on the interactive page.
- GO:0006813
- GO:0007520
- GO:0042127
- GO:0071277
- GO:0071805
- GO:0005886
- GO:0008076
- GO:0031901
- GO:0005251
- GO:0005515
- GO:1902936
Related records
Trials (336)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
- 4-aminopyridine for Skin Wound Healing
- 4-Aminopyridine in Episodic Ataxia Type 2
- 4-Aminopyridine to Treat Skin Burns
- 4-aminopyridine Treatment for Nerve Injury
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
- 4-AP Peripheral Nerve Crossover Trial
- 4AP for Carpal Tunnel Syndrome (CTS)
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium
- A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
- A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
- A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
- A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
Drugs (16)
- Amifampridine Voltage-gated potassium channel blocker
- Amifampridine phosphate Voltage-gated potassium channel blocker
- Astemizole
- Clofilium
- Clofilium phosphate
- Dalfampridine Voltage-gated potassium channel blocker
- Dofetilide
- Guanidine Voltage-gated potassium channel blocker
- Guanidine hydrochloride Voltage-gated potassium channel blocker
- Haloperidol
- Imipramine
- Nerispirdine Voltage-gated potassium channel blocker
- Quinidine
- Tedisamil Voltage-gated potassium channel blocker
- Tedisamil sesquifumarate Voltage-gated potassium channel blocker
- Terfenadine